Science/Resources
Check out recently published articles on Germicidal Ultraviolet (GUV) and the advantages of Boski Air products
Evidence of UV-C Effectiveness
Boski Advantages
UV-C Lighting 101
UV-C refers to ultraviolet light with wavelengths between 200 – 280 nanometers (nm). Light in the UV-C wavelength can be used for destroying dangerous micro-organisms and viruses in the air.
​
UV-C radiation, in the range of 250 nm - 280 nm, renders bacteria and viruses ineffective, by destroying the genetic information in the DNA. The germicidal nature of UV-C is well suited to treat parasites which are extremely resistant to chemical disinfectants.
​
UV-C's effect on Viruses
Studies have shown that UV radiation kills viruses by chemically modifying their genetic material, DNA, and RNA. Specifically, UV-C light has been shown to destroy various coronaviruses, including SARS-CoV-2 as outlined on this research article. For more information on UV-C's effectiveness against viruses, see our UV-C Resources page.
Boski's Technology Advantage
The vast majority of tabletop air sanitation/purification devices have not undergone 3rd party lab testing for efficacy against airborne viruses. In October, 2020, Boski completed 3rd party lab testing with ARE Labs in compliance with the FDA Good Laboratory Practices (GLP) as defined in 21 CFR, Part 58. Results showed a kill rate of 99.99%+ of MS2, a virus that is an excellent surrogate for COVID-19 as both are positive-sense single-stranded RNA, or (+)ssRNA viruses. MS2 is a non-enveloped virus which are harder to kill than enveloped viruses like COVID-19. To receive a copy of the official lab test report, Contact Us.
​
It is scientifically proven that air exposure time to UV-C light and the intensity of the UV-C light determine the efficacy of deactivating pathogens at their DNA level.
Boski's second generation air sanitation units will use a unique combination of fluid mechanical effects and advanced optical engineering designs to maximize the air-light interaction, creating optimum efficacy against airborne viruses and pathogens. This technology is patent-pending for U.S. Provisional Application No.: 63/036,861.
Download our Executive Overview: